Introduktion
Den här sidan ger en omfattande analys av den kända insiderhandelshistoriken för McAnear Justin J.. Insiders är tjänstemän, styrelseledamöter eller betydande investerare i ett företag. Det är olagligt för insiders att göra affärer i sina företag baserat på specifik, icke-offentlig information. Detta betyder inte att det är olagligt för dem att göra några affärer i sina egna företag. De måste dock rapportera alla affärer till SEC via ett formulär 4. Trots dessa restriktioner tyder akademisk forskning på att insiders – i allmänhet – tenderar att överträffa marknaden i sina egna företag.
Genomsnittlig handelslönsamhet
Den genomsnittliga handelslönsamheten är den genomsnittliga avkastningen av alla köp på den öppna marknaden som insidern gjort under de senaste tre åren. För att beräkna detta undersöker vi alla oplanerade köp på öppen marknad som görs av insidern, exklusive alla affärer som markerats som en del av en 10b5-1-handelsplan. Vi beräknar sedan den genomsnittliga prestandan för dessa affärer under 3, 6 och 12 månader, med ett genomsnitt av var och en av dessa varaktigheter för att generera ett slutgiltigt resultatmått för varje affär. Slutligen tar vi ett genomsnitt av alla prestationsmått för att beräkna ett prestationsmått för insidern. Denna lista inkluderar endast insiders som har gjort minst tre affärer under de senaste två åren.
Om lönsamheten för denna insiderhandel är "N/A", så har insidern antingen inte gjort några köp på den öppna marknaden under de senaste tre åren, eller så är affärerna de har gjort för nya för att kunna beräkna ett tillförlitligt resultatmått.
Uppdateringsfrekvens: Dagligen
Företag med rapporterade insiderpositioner
SEC-anmälningarna visar att McAnear Justin J. har rapporterat innehav eller affärer i följande företag:
Värdepapper | Titel | Senaste rapporterade innehav |
---|---|---|
US:TXG / 10x Genomics, Inc. | 143 242 |
Hur man tolkar diagrammen
Följande diagram visar aktieutvecklingen för värdepapper efter varje icke-planerad handel på öppen marknad som görs av McAnear Justin J.. Icke-planerad handel är affärer som inte gjordes som en del av en 10b5-1-handelsplan. Aktieutvecklingen visas som kumulativ procentuell förändring av aktiekursen. Till exempel, om en insiderhandel gjordes den 1 januari 2019, kommer diagrammet att visa den dagliga procentuella förändringen av värdepapperet fram till idag. Om aktiekursen skulle gå från $10 till $15 under denna tid, skulle den kumulativa procentuella förändringen i aktiekursen vara 50%. En förändring i priset från 10 USD till 20 USD skulle vara 100 % och en prisändring på 10 USD till 5 USD skulle vara -50 %.
I slutändan försöker vi avgöra hur nära insiders affärer korrelerar med överavkastning (positiv eller negativ) i aktiekursen för att se om insidern tar tid för sina affärer att dra nytta av insiderinformation. Tänk på situationen där en insider gjorde detta. I den här situationen förväntar vi oss antingen (a) positiv avkastning efter köp eller (b) negativ avkastning efter försäljning. I fallet med (a) skulle KÖP-diagrammet visa en serie uppåtlutande kurvor, vilket indikerar positiv avkastning efter varje köptransaktion. I fallet med (b) skulle SALE-diagrammet visa en serie nedåtlutande kurvor, vilket indikerar negativ avkastning efter varje försäljningstransaktion.
Detta är dock inte tillräckligt för att dra slutsatser. Om till exempel aktiekursen i bolaget var i en icke-cyklisk stigning under många år, skulle vi förvänta oss att alla tomter efter köpet skulle vara uppåtlutande. Likaså skulle icke-cykliska nedgångar under många år resultera i nedåtlutande post-trade tomter. Inget av dessa diagram skulle tyda på insiderhandel.
Den starkaste indikatorn skulle vara en situation där aktiekursen var extremt cyklisk, och det fanns både positiva signaler i KÖP-diagrammet och negativa plotter på SALE-diagrammet. Denna situation skulle i hög grad tyda på en insider som tog tid för affärer till sin ekonomiska fördel.
Insiderköp TXG / 10x Genomics, Inc. - Analys av kortsiktig vinst
I det här avsnittet analyserar vi lönsamheten för varje oplanerat insiderköp på en öppen marknad som görs i TXG / 10x Genomics, Inc.. Denna analys hjälper till att förstå om insidern konsekvent genererar onormal avkastning och är värd att följa. Denna analys är för ett år efter varje handel, och resultaten är teoretiska .
Tabellen nedan visar de senaste öppna marknadsköpen som inte var en del av en automatisk handelsplan.
Handelsdatum | Ticker | Insider | Rapporterade aktier |
Rapporterad pris |
Justerade aktier |
Justerat pris |
Kostnadsgrund | Dagar till max |
Pris vid max |
Max vinst ($) |
Maximal avkastning (%) |
---|---|---|---|---|---|---|---|---|---|---|---|
2022-05-13 | TXG | McAnear Justin J. | 158 | 40,4855 | 158 | 40,4855 | 6 397 | 322 | 55.7900 | 2 419 | 37,82 |
Det justerade prisetär det justerade priset efter split. Justerade aktier er de split-justerade aktier.
Insiderförsäljning - Analys av kortsiktig förlust
I det här avsnittet analyserar vi det kortsiktiga undvikandet av förluster för varje oplanerad insiderförsäljning på öppen marknad som görs i TXG / 10x Genomics, Inc.. Ett konsekvent mönster för att undvika förluster kan tyda på att framtida försäljningstransaktioner kan förutsäga prisnedgångar. Denna analys är för ett år efter varje handel, och resultaten är teoretiska .
Följande tabell visar de senaste försäljningarna på den öppna marknaden som inte ingick i en automatisk handelsplan.
Det justerade prisetär det justerade priset efter split. Justerade aktier er de split-justerade aktier.
Insiderhandelshistorik
Den här tabellen visar den fullständiga listan över insideraffärer gjorda av McAnear Justin J. som avslöjats för Securities Exchange Commission (SEC).
Fildatum | Transaktionsdatum | Schema | Ticker | Värdepapper | Kode | Aktier | Återstående aktier | Procentuell förandring | Aktie pris |
Transaktionsvärde | Återstående värde |
|
---|---|---|---|---|---|---|---|---|---|---|---|---|
2024-08-26 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | −2 961 | 143 242 | −2,03 | 22,53 | −66 710 | 3 227 199 | |
2024-05-23 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | −2 936 | 146 203 | −1,97 | 24,30 | −71 355 | 3 553 259 | |
2024-03-25 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
A - Award | 53 312 | 148 552 | 55,98 | ||||
2024-02-26 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | −1 865 | 95 240 | −1,92 | 46,34 | −86 432 | 4 413 831 | |
2023-11-27 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | −1 679 | 97 105 | −1,70 | 43,34 | −72 762 | 4 208 210 | |
2023-08-24 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | −1 678 | 98 784 | −1,67 | 45,78 | −76 821 | 4 522 440 | |
2023-05-25 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | −565 | 100 462 | −0,56 | 55,06 | −31 111 | 5 531 809 | |
2023-05-25 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | −441 | 101 027 | −0,43 | 55,06 | −24 283 | 5 562 961 | |
2023-05-25 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | −465 | 101 468 | −0,46 | 55,06 | −25 604 | 5 587 041 | |
2023-05-25 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | −194 | 101 933 | −0,19 | 55,07 | −10 683 | 5 613 399 | |
2023-03-23 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
A - Award | 25 991 | 101 510 | 34,42 | ||||
2023-02-24 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | −1 245 | 75 519 | −1,62 | 47,75 | −59 453 | 3 606 281 | |
2022-11-23 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | −288 | 76 764 | −0,37 | 34,07 | −9 811 | 2 615 081 | |
2022-11-23 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | −652 | 77 052 | −0,84 | 34,07 | −22 212 | 2 625 000 | |
2022-11-23 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | −686 | 77 704 | −0,88 | 34,07 | −23 369 | 2 646 995 | |
2022-09-16 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
A - Award | 20 297 | 78 389 | 34,94 | ||||
2022-08-25 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | −987 | 58 092 | −1,67 | 35,19 | −34 734 | 2 044 333 | |
2022-05-25 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | −967 | 59 079 | −1,61 | 48,76 | −47 155 | 2 880 934 | |
2022-05-17 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
P - Purchase | 158 | 60 046 | 0,26 | 40,49 | 6 397 | 2 430 992 | |
2022-03-24 |
|
4 | TXG |
10x Genomics, Inc.
Stock Option (Right to Buy) |
A - Award | 53 392 | 53 392 | |||||
2022-03-24 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
A - Award | 21 357 | 59 888 | 55,43 | ||||
2022-02-24 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | −288 | 38 531 | −0,74 | 78,60 | −22 637 | 3 028 513 | |
2022-01-05 |
|
4 | TXG |
10x Genomics, Inc.
Stock Option (right to buy) |
M - Exercise | X | −10 000 | 350 159 | −2,78 | |||
2022-01-05 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −500 | 38 819 | −1,27 | 149,18 | −74 589 | 5 790 941 |
2022-01-05 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −500 | 39 319 | −1,26 | 148,04 | −74 022 | 5 820 942 |
2022-01-05 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −1 334 | 39 819 | −3,24 | 146,92 | −195 988 | 5 850 120 |
2022-01-05 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −4 083 | 41 153 | −9,03 | 145,96 | −595 937 | 6 006 511 |
2022-01-05 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −3 583 | 45 236 | −7,34 | 145,16 | −520 115 | 6 566 544 |
2022-01-05 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
M - Exercise | X | 10 000 | 48 819 | 25,76 | 5,04 | 50 400 | 246 048 |
2021-12-03 |
|
4 | TXG |
10x Genomics, Inc.
Stock Option (right to buy) |
M - Exercise | X | −10 000 | 360 159 | −2,70 | |||
2021-12-03 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −100 | 38 819 | −0,26 | 155,55 | −15 555 | 6 038 295 |
2021-12-03 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −200 | 38 919 | −0,51 | 153,86 | −30 772 | 5 987 984 |
2021-12-03 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −300 | 39 119 | −0,76 | 151,80 | −45 539 | 5 938 135 |
2021-12-03 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −300 | 39 419 | −0,76 | 151,31 | −45 394 | 5 964 674 |
2021-12-03 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −500 | 39 719 | −1,24 | 150,71 | −75 357 | 5 986 209 |
2021-12-03 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −600 | 40 219 | −1,47 | 149,40 | −89 643 | 6 008 920 |
2021-12-03 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −1 302 | 40 819 | −3,09 | 148,48 | −193 321 | 6 060 805 |
2021-12-03 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −2 700 | 42 121 | −6,02 | 147,62 | −398 563 | 6 217 725 |
2021-12-03 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −1 536 | 44 821 | −3,31 | 146,49 | −225 014 | 6 565 994 |
2021-12-03 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −2 462 | 46 357 | −5,04 | 145,54 | −358 323 | 6 746 867 |
2021-12-03 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
M - Exercise | X | 10 000 | 48 819 | 25,76 | 5,04 | 50 400 | 246 048 |
2021-11-24 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | −281 | 38 819 | −0,72 | 148,38 | −41 695 | 5 760 006 | |
2021-11-03 |
|
4 | TXG |
10x Genomics, Inc.
Stock Option (right to buy) |
M - Exercise | X | −10 000 | 370 159 | −2,63 | |||
2021-11-03 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −200 | 39 100 | −0,51 | 164,96 | −32 992 | 6 450 014 |
2021-11-03 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −4 333 | 39 300 | −9,93 | 164,05 | −710 847 | 6 447 330 |
2021-11-03 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −4 667 | 43 633 | −9,66 | 163,34 | −762 314 | 7 127 075 |
2021-11-03 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −500 | 48 300 | −1,02 | 162,16 | −81 079 | 7 832 217 |
2021-11-03 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −300 | 48 800 | −0,61 | 160,48 | −48 142 | 7 831 180 |
2021-11-03 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
M - Exercise | X | 10 000 | 49 100 | 25,58 | 5,04 | 50 400 | 247 464 |
2021-10-05 |
|
4 | TXG |
10x Genomics, Inc.
Stock Option (right to buy) |
M - Exercise | X | −10 000 | 380 159 | −2,56 | |||
2021-10-05 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −1 200 | 39 100 | −2,98 | 144,57 | −173 485 | 5 652 718 |
2021-10-05 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −5 666 | 40 300 | −12,33 | 143,79 | −814 725 | 5 794 814 |
2021-10-05 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −2 500 | 45 966 | −5,16 | 142,80 | −357 008 | 6 564 087 |
2021-10-05 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −634 | 48 466 | −1,29 | 141,96 | −90 003 | 6 880 282 |
2021-10-05 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
M - Exercise | X | 10 000 | 49 100 | 25,58 | 5,04 | 50 400 | 247 464 |
2021-09-03 |
|
4 | TXG |
10x Genomics, Inc.
Stock Option (right to buy) |
M - Exercise | X | −10 000 | 390 159 | −2,50 | |||
2021-09-03 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −1 540 | 39 100 | −3,79 | 178,80 | −275 358 | 6 991 240 |
2021-09-03 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −4 747 | 40 640 | −10,46 | 177,87 | −844 359 | 7 228 726 |
2021-09-03 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −2 200 | 45 387 | −4,62 | 177,00 | −389 396 | 8 033 417 |
2021-09-03 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −1 139 | 47 587 | −2,34 | 175,95 | −200 412 | 8 373 133 |
2021-09-03 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −374 | 48 726 | −0,76 | 174,87 | −65 401 | 8 520 716 |
2021-09-03 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
M - Exercise | X | 10 000 | 49 100 | 25,58 | 5,04 | 50 400 | 247 464 |
2021-08-25 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | −270 | 39 100 | −0,69 | 161,85 | −43 699 | 6 328 237 | |
2021-08-04 |
|
4 | TXG |
10x Genomics, Inc.
Stock Option (right to buy) |
M - Exercise | X | −10 000 | 400 159 | −2,44 | |||
2021-08-04 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −300 | 39 370 | −0,76 | 184,52 | −55 357 | 7 264 682 |
2021-08-04 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −500 | 39 670 | −1,24 | 183,30 | −91 650 | 7 271 511 |
2021-08-04 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −700 | 40 170 | −1,71 | 182,16 | −127 514 | 7 317 484 |
2021-08-04 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −2 302 | 40 870 | −5,33 | 181,31 | −417 376 | 7 410 144 |
2021-08-04 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −2 298 | 43 172 | −5,05 | 180,29 | −414 304 | 7 783 437 |
2021-08-04 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −2 202 | 45 470 | −4,62 | 179,28 | −394 780 | 8 151 975 |
2021-08-04 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −1 698 | 47 672 | −3,44 | 178,35 | −302 840 | 8 502 344 |
2021-08-04 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
M - Exercise | X | 10 000 | 49 370 | 25,40 | 5,04 | 50 400 | 248 825 |
2021-07-06 |
|
4 | TXG |
10x Genomics, Inc.
Stock Option (right to buy) |
M - Exercise | X | −10 000 | 410 159 | −2,38 | |||
2021-07-06 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −100 | 39 370 | −0,25 | 195,82 | −19 582 | 7 709 433 |
2021-07-06 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −700 | 39 470 | −1,74 | 194,81 | −136 364 | 7 688 969 |
2021-07-06 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −1 400 | 40 170 | −3,37 | 193,76 | −271 268 | 7 783 456 |
2021-07-06 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −800 | 41 570 | −1,89 | 192,95 | −154 358 | 8 020 819 |
2021-07-06 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −1 500 | 42 370 | −3,42 | 191,73 | −287 602 | 8 123 799 |
2021-07-06 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −2 800 | 43 870 | −6,00 | 190,66 | −533 859 | 8 364 421 |
2021-07-06 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −2 700 | 46 670 | −5,47 | 189,85 | −512 601 | 8 860 402 |
2021-07-06 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
M - Exercise | X | 10 000 | 49 370 | 25,40 | 5,04 | 50 400 | 248 825 |
2021-06-03 |
|
4 | TXG |
10x Genomics, Inc.
Stock Option (right to buy) |
M - Exercise | X | −10 000 | 420 159 | −2,32 | |||
2021-06-03 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −300 | 39 011 | −0,76 | 180,02 | −54 007 | 7 022 889 |
2021-06-03 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −200 | 39 311 | −0,51 | 179,21 | −35 842 | 7 044 826 |
2021-06-03 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −300 | 39 511 | −0,75 | 178,07 | −53 420 | 7 035 593 |
2021-06-03 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −2 906 | 39 811 | −6,80 | 175,77 | −510 786 | 6 997 560 |
2021-06-03 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −1 994 | 42 717 | −4,46 | 174,93 | −348 808 | 7 472 425 |
2021-06-03 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −1 000 | 44 711 | −2,19 | 173,94 | −173 944 | 7 777 210 |
2021-06-03 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −800 | 45 711 | −1,72 | 172,85 | −138 279 | 7 901 064 |
2021-06-03 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −2 500 | 46 511 | −5,10 | 171,59 | −428 984 | 7 980 999 |
2021-06-03 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
M - Exercise | X | 10 000 | 49 011 | 25,63 | 5,04 | 50 400 | 247 015 |
2021-05-26 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | −281 | 39 011 | −0,72 | 162,66 | −45 707 | 6 345 514 | |
2021-05-26 |
|
4 | TXG |
10x Genomics, Inc.
Stock Option (right to buy) |
A - Award | 22 338 | 22 338 | |||||
2021-05-26 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
A - Award | 8 935 | 39 292 | 29,43 | ||||
2021-05-05 |
|
4 | TXG |
10x Genomics, Inc.
Stock Option (right to buy) |
M - Exercise | X | −10 000 | 430 159 | −2,27 | |||
2021-05-05 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −100 | 30 357 | −0,33 | 198,09 | −19 809 | 6 013 418 |
2021-05-05 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −200 | 30 457 | −0,65 | 194,92 | −38 984 | 5 936 678 |
2021-05-05 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −794 | 30 657 | −2,52 | 193,40 | −153 560 | 5 929 067 |
2021-05-05 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −3 706 | 31 451 | −10,54 | 192,46 | −713 241 | 6 052 927 |
2021-05-05 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −2 700 | 35 157 | −7,13 | 191,77 | −517 783 | 6 742 114 |
2021-05-05 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −1 900 | 37 857 | −4,78 | 190,63 | −362 191 | 7 216 563 |
2021-05-05 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −600 | 39 757 | −1,49 | 189,57 | −113 743 | 7 536 806 |
2021-05-05 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
M - Exercise | X | 10 000 | 40 357 | 32,94 | 5,04 | 50 400 | 203 399 |
2021-04-02 |
|
4 | TXG |
10x Genomics, Inc.
Stock Option (right to buy) |
M - Exercise | X | −10 000 | 440 159 | −2,22 | |||
2021-04-02 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −1 800 | 30 357 | −5,60 | 185,76 | −334 361 | 5 638 998 |
2021-04-02 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −3 795 | 32 157 | −10,56 | 185,02 | −702 152 | 5 949 698 |
2021-04-02 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −3 205 | 35 952 | −8,18 | 184,12 | −590 096 | 6 619 382 |
2021-04-02 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −700 | 39 157 | −1,76 | 183,19 | −128 231 | 7 173 057 |
2021-04-02 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −200 | 39 857 | −0,50 | 181,82 | −36 365 | 7 246 999 |
2021-04-02 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −300 | 40 057 | −0,74 | 180,02 | −54 007 | 7 211 193 |
2021-04-02 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
M - Exercise | X | 10 000 | 40 357 | 32,94 | 5,04 | 50 400 | 203 399 |
2021-03-10 |
|
4 | TXG |
10x Genomics, Inc.
Stock Option (right to buy) |
M - Exercise | −9 583 | 10 417 | −47,92 | ||||
2021-03-10 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
M - Exercise | 9 583 | 30 357 | 46,13 | 11,48 | 110 013 | 348 498 | |
2021-03-10 |
|
4 | TXG |
10x Genomics, Inc.
Stock Option (right to buy) |
M - Exercise | X | −10 000 | 450 159 | −2,17 | |||
2021-03-10 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −100 | 20 774 | −0,48 | 154,82 | −15 482 | 3 216 231 |
2021-03-10 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −300 | 20 874 | −1,42 | 154,14 | −46 241 | 3 217 449 |
2021-03-10 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −400 | 21 174 | −1,85 | 152,08 | −60 833 | 3 220 195 |
2021-03-10 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −800 | 21 574 | −3,58 | 151,22 | −120 977 | 3 262 448 |
2021-03-10 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −1 200 | 22 374 | −5,09 | 150,22 | −180 261 | 3 360 966 |
2021-03-10 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −1 100 | 23 574 | −4,46 | 149,43 | −164 371 | 3 522 620 |
2021-03-10 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −200 | 24 674 | −0,80 | 148,08 | −29 616 | 3 653 726 |
2021-03-10 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −1 476 | 24 874 | −5,60 | 146,88 | −216 793 | 3 653 453 |
2021-03-10 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −1 902 | 26 350 | −6,73 | 145,90 | −277 501 | 3 844 460 |
2021-03-10 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −1 100 | 28 252 | −3,75 | 145,03 | −159 528 | 4 097 260 |
2021-03-10 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −400 | 29 352 | −1,34 | 142,48 | −56 994 | 4 182 220 |
2021-03-10 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −1 022 | 29 752 | −3,32 | 141,25 | −144 357 | 4 202 467 |
2021-03-10 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
M - Exercise | X | 10 000 | 30 774 | 48,14 | 5,04 | 50 400 | 155 101 |
2021-02-03 |
|
4 | TXG |
10x Genomics, Inc.
Stock Option (right to buy) |
M - Exercise | X | −10 000 | 460 159 | −2,13 | |||
2021-02-03 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −500 | 20 774 | −2,35 | 178,49 | −89 247 | 3 708 034 |
2021-02-03 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −910 | 21 274 | −4,10 | 177,50 | −161 525 | 3 776 139 |
2021-02-03 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −2 777 | 22 184 | −11,13 | 176,51 | −490 171 | 3 915 718 |
2021-02-03 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −5 213 | 24 961 | −17,28 | 175,53 | −915 027 | 4 381 352 |
2021-02-03 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −600 | 30 174 | −1,95 | 174,18 | −104 509 | 5 255 759 |
2021-02-03 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
M - Exercise | X | 10 000 | 30 774 | 48,14 | 5,04 | 50 400 | 155 101 |
2021-01-06 |
|
4 | TXG |
10x Genomics, Inc.
Stock Option (right to buy) |
M - Exercise | X | −10 000 | 470 159 | −2,08 | |||
2021-01-06 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −200 | 20 774 | −0,95 | 141,91 | −28 382 | 2 948 038 |
2021-01-06 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −1 764 | 20 974 | −7,76 | 140,78 | −248 331 | 2 952 659 |
2021-01-06 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −6 036 | 22 738 | −20,98 | 139,91 | −844 525 | 3 181 380 |
2021-01-06 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −2 000 | 28 774 | −6,50 | 139,08 | −278 152 | 4 001 776 |
2021-01-06 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
M - Exercise | X | 10 000 | 30 774 | 48,14 | 5,04 | 50 400 | 155 101 |
2020-12-28 |
|
4 | TXG |
10x Genomics, Inc.
Stock Option (right to buy) |
M - Exercise | −19 841 | 480 159 | −3,97 | ||||
2020-12-28 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
M - Exercise | 19 841 | 20 774 | 2 126,58 | 5,04 | 99 999 | 104 701 | |
2020-12-03 |
|
4 | TXG |
10x Genomics, Inc.
Stock Option (right to buy) |
M - Exercise | X | −10 000 | 500 000 | −1,96 | |||
2020-12-03 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −500 | 933 | −34,89 | 153,79 | −76 897 | 143 490 |
2020-12-03 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −2 108 | 1 433 | −59,53 | 153,21 | −322 965 | 219 549 |
2020-12-03 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −1 600 | 3 541 | −31,12 | 151,80 | −242 883 | 537 531 |
2020-12-03 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −3 168 | 5 141 | −38,13 | 150,94 | −478 186 | 775 995 |
2020-12-03 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −2 624 | 8 309 | −24,00 | 150,03 | −393 680 | 1 246 604 |
2020-12-03 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
M - Exercise | X | 10 000 | 10 933 | 1 071,81 | 5,04 | 50 400 | 55 102 |
2020-11-04 |
|
4 | TXG |
10x Genomics, Inc.
Stock Option (right to buy) |
M - Exercise | X | −2 900 | 510 000 | −0,57 | |||
2020-11-04 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −100 | 933 | −9,68 | 138,73 | −13 873 | 129 435 |
2020-11-04 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −1 600 | 1 033 | −60,77 | 137,57 | −220 119 | 142 114 |
2020-11-04 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −1 000 | 2 633 | −27,53 | 136,54 | −136 544 | 359 520 |
2020-11-04 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −200 | 3 633 | −5,22 | 135,55 | −27 110 | 492 453 |
2020-11-04 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
M - Exercise | X | 2 900 | 3 833 | 310,83 | 5,04 | 14 616 | 19 318 |
2020-11-04 |
|
4 | TXG |
10x Genomics, Inc.
Stock Option (right to buy) |
M - Exercise | X | −7 100 | 512 900 | −1,37 | |||
2020-11-04 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −400 | 933 | −30,01 | 139,21 | −55 684 | 129 883 |
2020-11-04 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −500 | 1 333 | −27,28 | 137,99 | −68 995 | 183 941 |
2020-11-04 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −500 | 1 833 | −21,43 | 137,10 | −68 552 | 251 312 |
2020-11-04 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −4 376 | 2 333 | −65,23 | 136,10 | −595 581 | 317 525 |
2020-11-04 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −1 324 | 6 709 | −16,48 | 135,40 | −179 264 | 908 370 |
2020-11-04 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
M - Exercise | X | 7 100 | 8 033 | 760,99 | 5,04 | 35 784 | 40 486 |
2020-10-05 |
|
4 | TXG |
10x Genomics, Inc.
Stock Option (right to buy) |
M - Exercise | X | −10 000 | 520 000 | −1,89 | |||
2020-10-05 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −100 | 933 | −9,68 | 126,88 | −12 688 | 118 379 |
2020-10-05 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −2 988 | 1 033 | −74,31 | 125,98 | −376 419 | 130 134 |
2020-10-05 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −5 612 | 4 021 | −58,26 | 125,48 | −704 219 | 504 573 |
2020-10-05 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −1 300 | 9 633 | −11,89 | 124,19 | −161 448 | 1 196 330 |
2020-10-05 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
M - Exercise | X | 10 000 | 10 933 | 1 071,81 | 5,04 | 50 400 | 55 102 |
2020-09-03 |
|
4 | TXG |
10x Genomics, Inc.
Stock Option (right to buy) |
M - Exercise | X | −10 000 | 530 000 | −1,85 | |||
2020-09-03 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −215 | 933 | −18,73 | 115,52 | −24 837 | 107 780 |
2020-09-03 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −2 684 | 1 148 | −70,04 | 114,78 | −308 078 | 131 771 |
2020-09-03 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −5 201 | 3 832 | −57,58 | 113,83 | −592 045 | 436 208 |
2020-09-03 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −1 900 | 9 033 | −17,38 | 112,91 | −214 527 | 1 019 904 |
2020-09-03 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
M - Exercise | X | 10 000 | 10 933 | 1 071,81 | 5,04 | 50 400 | 55 102 |
2020-08-05 |
|
4 | TXG |
10x Genomics, Inc.
Stock Option (right to buy) |
M - Exercise | X | −10 000 | 540 000 | −1,82 | |||
2020-08-05 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −800 | 933 | −46,16 | 100,76 | −80 610 | 94 011 |
2020-08-05 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −6 348 | 1 733 | −78,55 | 99,39 | −630 904 | 172 236 |
2020-08-05 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −2 852 | 8 081 | −26,09 | 98,85 | −281 916 | 798 796 |
2020-08-05 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
M - Exercise | X | 10 000 | 10 933 | 1 071,81 | 5,04 | 50 400 | 55 102 |
2020-07-02 |
|
4 | TXG |
10x Genomics, Inc.
Stock Option (right to buy) |
M - Exercise | X | −10 000 | 550 000 | −1,79 | |||
2020-07-02 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −100 | 0 | −100,00 | 88,63 | −8 863 | |
2020-07-02 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −4 779 | 100 | −97,95 | 88,03 | −420 695 | 8 803 |
2020-07-02 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −5 121 | 4 879 | −51,21 | 87,18 | −446 439 | 425 342 |
2020-07-02 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
M - Exercise | X | 10 000 | 10 000 | 5,04 | 50 400 | 50 400 | |
2020-06-03 |
|
4 | TXG |
10x Genomics, Inc.
Stock Option (right to buy) |
M - Exercise | X | −10 000 | 560 000 | −1,75 | |||
2020-06-03 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −1 800 | 0 | −100,00 | 81,84 | −147 321 | |
2020-06-03 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −2 200 | 1 800 | −55,00 | 81,27 | −178 797 | 146 289 |
2020-06-03 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −1 600 | 4 000 | −28,57 | 80,02 | −128 029 | 320 072 |
2020-06-03 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −1 400 | 5 600 | −20,00 | 79,08 | −110 714 | 442 856 |
2020-06-03 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −2 100 | 7 000 | −23,08 | 78,00 | −163 804 | 546 012 |
2020-06-03 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −900 | 9 100 | −9,00 | 77,09 | −69 378 | 701 494 |
2020-06-03 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
M - Exercise | X | 10 000 | 10 000 | 5,04 | 50 400 | 50 400 | |
2020-05-05 |
|
4 | TXG |
10x Genomics, Inc.
Stock Option (right to buy) |
M - Exercise | X | −10 000 | 570 000 | −1,72 | |||
2020-05-05 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −2 600 | 0 | −100,00 | 78,70 | −204 631 | |
2020-05-05 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −2 010 | 2 600 | −43,60 | 77,66 | −156 097 | 201 917 |
2020-05-05 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −5 390 | 4 610 | −53,90 | 76,64 | −413 110 | 353 327 |
2020-05-05 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
M - Exercise | X | 10 000 | 10 000 | 5,04 | 50 400 | 50 400 | |
2020-04-23 |
|
4 | TXG |
10x Genomics, Inc.
Stock Option (right to buy) |
A - Award | 90 667 | 90 667 | |||||
2020-04-03 |
|
4 | TXG |
10x Genomics, Inc.
Stock Option (right to buy) |
M - Exercise | X | −10 000 | 580 000 | −1,69 | |||
2020-04-03 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −200 | 0 | −100,00 | 59,82 | −11 964 | |
2020-04-03 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −5 110 | 200 | −96,23 | 58,32 | −298 025 | 11 664 |
2020-04-03 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −4 690 | 5 310 | −46,90 | 57,76 | −270 889 | 306 699 |
2020-04-03 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
M - Exercise | X | 10 000 | 10 000 | 5,04 | 50 400 | 50 400 | |
2020-03-09 |
|
4 | TXG |
10x Genomics, Inc.
Stock Option (right to buy) |
M - Exercise | X | −10 000 | 590 000 | −1,67 | |||
2020-03-09 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −1 225 | 0 | −100,00 | 69,68 | −85 359 | |
2020-03-09 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −900 | 1 225 | −42,35 | 68,26 | −61 432 | 83 616 |
2020-03-09 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −600 | 2 125 | −22,02 | 66,74 | −40 047 | 141 833 |
2020-03-09 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −700 | 2 725 | −20,44 | 65,72 | −46 002 | 179 079 |
2020-03-09 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −1 940 | 3 425 | −36,16 | 64,58 | −125 280 | 221 178 |
2020-03-09 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −2 835 | 5 365 | −34,57 | 63,65 | −180 439 | 341 465 |
2020-03-09 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
S - Sale | X | −1 800 | 8 200 | −18,00 | 62,77 | −112 993 | 514 746 |
2020-03-09 |
|
4 | TXG |
10x Genomics, Inc.
Class A Common Stock |
M - Exercise | X | 10 000 | 10 000 | 5,04 | 50 400 | 50 400 | |
2019-09-16 |
|
4 | TXG |
10x Genomics, Inc.
Stock Option (right to buy) |
J - Other | 20 000 | 20 000 | |||||
2019-09-16 |
|
4 | TXG |
10x Genomics, Inc.
Stock Option (right to buy) |
J - Other | −20 000 | 0 | −100,00 | ||||
2019-09-16 |
|
4 | TXG |
10x Genomics, Inc.
Stock Option (right to buy) |
J - Other | 600 000 | 600 000 | |||||
2019-09-16 |
|
4 | TXG |
10x Genomics, Inc.
Stock Option (right to buy) |
J - Other | −600 000 | 0 | −100,00 |